The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

作者：N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman, Monika Bullinger, A. Cull, N. Duez, A. Filiberti, Hans‐Henning Flechtner, Stewart B. Fleishman, J.C.J.M. de Haes, S. Kaasa, M. Klee, David Osoba, Darius Razavi, Peter B. C. Rofe, S Schraub, K.C.A. Sneeuw, Marianne Sullivan, Fumikazu Takeda · 发表于：JNCI Journal of the National Cancer Institute · 年份：1993 · DOI：10.1093/jnci/85.5.365 · 被引用次数：16178 · 研究领域：Cancer survivorship and care、Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment

BACKGROUND: In 1986, the European Organization for Research and Treatment of Cancer (EORTC) initiated a research program to develop an integrated, modular approach for evaluating the quality of life of patients participating in international clinical trials. PURPOSE: We report here the results of an international field study of the practicality, reliability, and validity of the EORTC QLQ-C30, the current core questionnaire. The QLQ-C30 incorporates nine multi-item scales: five functional scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and nausea and vomiting); and a global health and quality-of-life scale. Several single-item symptom measures are also included. METHODS: The questionnaire was administered before treatment and once during treatment to 305 patients with nonresectable lung cancer from centers in 13 countries. Clinical variables assessed included disease stage, weight loss, performance status, and treatment toxicity. RESULTS: The average time required to complete the questionnaire was approximately 11 minutes, and most patients required no assistance. The data supported the hypothesized scale structure of the questionnaire with the exception of role functioning (work and household activities), which was also the only multi-item scale that failed to meet the minimal standards for reliability (Cronbach's alpha coefficient > or = .70) either before or during treatment. Validity was shown by three findings. First, while ...